Ironwood Pharmaceuticals to Present HCP Insights on TPN Burden in Short Bowel Syndrome at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Present Real-World Clinician Insights on Total Parenteral Nutrition Burden in Short Bowel Syndrome at Digestive Disease Week® 2026 Ironwood Pharmaceuticals, Inc. has announced that it will present…

Read MoreIronwood Pharmaceuticals to Present HCP Insights on TPN Burden in Short Bowel Syndrome at Digestive Disease Week® 2026

IMAAVY® (nipocalimab-aahu) Demonstrates Sustained Disease Control Beyond Two Years Across a Broad gMG Patient Population

IMAAVY® (nipocalimab-aahu) Demonstrates Durable, Over Two-Year Disease Control Across a Broad gMG Patient Population Johnson & Johnson has unveiled new clinical findings highlighting the long-term efficacy and safety of IMAAVY®…

Read MoreIMAAVY® (nipocalimab-aahu) Demonstrates Sustained Disease Control Beyond Two Years Across a Broad gMG Patient Population

Late-Breaking PRESERVE Trial Data Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation

Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results…

Read MoreLate-Breaking PRESERVE Trial Data Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation

Kennel Connection Forms Exclusive Diagnostic Partnership with Petwealth to Expand Clinical-Grade Pet Health Screening Nationwide

Kennel Connection Forms Exclusive Partnership with Petwealth to Deliver Clinical-Grade Pet Health Screening Across Pet Care Facilities Nationwide Kennel Connection, a leading provider of pet care facility management software and…

Read MoreKennel Connection Forms Exclusive Diagnostic Partnership with Petwealth to Expand Clinical-Grade Pet Health Screening Nationwide

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting

Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for…

Read MoreKallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting